TransMedics Group Inc. (TMDX)
NASDAQ: TMDX · Electromedical & Electrotherapeutic Apparatus · Andover, MA
Our rating: Neutral
Call changed from Positive to Neutral at $88.24, moderate conviction, November 6, 2026.
Breaks if: The Neutral call turns Cautious if revenue growth decelerates below 20% year-over-year in either of the next two quarterly reports, or if adverse patent rulings bring the cumulative count above five within 180 days of November 2026, indicating a systematic sweep of the IP estate rather than isolated challenges. It turns Positive if revenue growth holds at or above 35% through the next two quarterly prints and no further core OCS platform patents are invalidated over the same period.
Key figures
| Market value | $3.0B |
|---|---|
| Revenue, last 12 months | $728M |
| Net income, last 12 months | $144M |
| Free cash flow, last 12 months | $45M |
| Price to earnings | 20.5× |
| Free cash flow yield | 1.5% |
| Dividend yield | 0.0% |
| Operating margin | 11.9% |
| Return on equity | 31.9% |
| Beta to the S&P 500 | 1.23 |
| Volatility, annualized | 64.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $203M | 41.1% | $0.46 | $28M |
| June 30, 2026 | $190M | 20.7% | $0.41 | $10M |
| March 31, 2026 | $174M | 21.2% | $0.20 | −$12M |
| December 31, 2025 | $161M | 32.2% | $2.59 | $19M |
| September 30, 2025 | $144M | 32.2% | $0.66 | $62M |
| June 30, 2025 | $157M | 37.7% | $0.92 | $83M |
| March 31, 2025 | $144M | 48.2% | $0.70 | −$30M |
| December 31, 2024 | $122M | 49.8% | $0.20 | $6M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.21B: Claude 72%, Gemini 85%, Mistral 88%
- Diluted earnings per share are at least $2.59: Claude 28%, Gemini 10%, Mistral 5%
- Free cash flow for the quarter is at least $0.02B: Claude 55%, Gemini 75%, Mistral 60%
10 ledger entries and 38 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.